当前位置:首页 - 行情中心 - 新芝生物(920685) - 财务分析 - 现金流量表

新芝生物

(920685)

  

流通市值:0.00万  总市值:0.00万
流通股本:0.00万   总股本:0.00万

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金82,328,815.938,111,475.59190,015,716.45127,076,076.33
  收到的税费返还1,619,065.231,075,771.393,581,243.382,685,057.4
  收到其他与经营活动有关的现金2,917,053.451,292,527.968,300,947.034,807,436.11
  经营活动现金流入小计86,864,934.5840,479,774.94201,897,906.86134,568,569.84
  购买商品、接受劳务支付的现金20,757,146.528,456,537.0251,214,596.9631,291,671.28
  支付给职工以及为职工支付的现金37,702,266.4425,606,348.6164,748,600.153,625,067.97
  支付的各项税费13,785,611.347,991,223.5217,341,925.599,904,791.64
  支付其他与经营活动有关的现金8,501,207.84,182,447.4417,587,991.0916,494,153.63
  经营活动现金流出小计80,746,232.146,236,556.59150,893,113.74111,315,684.52
  经营活动产生的现金流量净额6,118,702.48-5,756,781.6551,004,793.1223,252,885.32
二、投资活动产生的现金流量:
  收回投资收到的现金628,450,400.4283,774,753.8914,000,000706,000,000
  取得投资收益收到的现金1,965,565.021,083,988.595,583,381.414,490,370.69
  处置固定资产、无形资产和其他长期资产收回的现金净额190,000190,00022,571,655.22,000,000
  投资活动现金流入小计630,605,965.42285,048,742.39942,155,036.61712,490,370.69
  购建固定资产、无形资产和其他长期资产支付的现金23,281,930.8411,468,955.6569,834,244.5954,315,004.54
  投资支付的现金603,297,107.74218,642,069.38909,000,000608,000,000
  取得子公司及其他营业单位支付的现金--5,804,750.065,804,750.06
  投资活动现金流出小计626,579,038.58230,111,025.03984,638,994.65668,119,754.6
  投资活动产生的现金流量净额4,026,926.8454,937,717.36-42,483,958.0444,370,616.09
三、筹资活动产生的现金流量:
  吸收投资收到的现金--850,000700,000
  其中:子公司吸收少数股东投资收到的现金--850,000-
  筹资活动现金流入平衡项目--00
  筹资活动现金流入小计--850,000700,000
  分配股利、利润或偿付利息支付的现金25,045,746.719,047,619.0535,551,394.835,551,394.8
  其中:子公司支付给少数股东的股利、利润-9,047,619.05--
  支付其他与筹资活动有关的现金1,300,587.96482,278.475,905,350.443,342,950.38
  筹资活动现金流出小计26,346,334.679,529,897.5241,456,745.2438,894,345.18
  筹资活动产生的现金流量净额-26,346,334.67-9,529,897.52-40,606,745.24-38,194,345.18
四、汇率变动对现金及现金等价物的影响-938.56-4,046.18-62,427.7426,335.59
五、现金及现金等价物净增加额-16,201,643.9139,646,992.01-32,148,337.929,455,491.82
  加:期初现金及现金等价物余额95,439,922.8895,439,922.88127,588,260.78127,588,260.78
  期末现金及现金等价物余额79,238,278.97135,086,914.8995,439,922.88157,043,752.6
补充资料:
  净利润15,144,602.06-51,647,030.17-
  资产减值准备1,298,986.72-1,804,158.47-
  固定资产和投资性房地产折旧2,162,171.32-4,916,301.93-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧2,162,171.32-4,916,301.93-
  无形资产摊销302,705.92-772,759.28-
  长期待摊费用摊销513,902.35-1,118,853.59-
  处置固定资产、无形资产和其他长期资产的损失---13,680,415.14-
  固定资产报废损失--11,972.2-
  公允价值变动损失-1,598,663.34--3,163,765.13-
  财务费用37,949.43-248,672.16-
  投资损失-1,125,535.31--2,752,930.97-
  递延所得税111,122.34-1,302,129.37-
  其中:递延所得税资产减少118,925.42-1,303,528.37-
    递延所得税负债增加-7,803.08--1,399-
  存货的减少-4,721,905.06-4,753,428.73-
  经营性应收项目的减少4,219,542.34--5,296,102.05-
  经营性应付项目的增加-11,638,030.14-4,375,983.64-
  其他-224,648.43-1,323,650-
  不涉及现金收支的投资和筹资活动金额其他项目--0-
  现金的期末余额79,238,278.97-95,439,922.88-
  减:现金的期初余额95,439,922.88-127,588,260.78-
  现金及现金等价物的净增加额-16,201,643.91--32,148,337.9-
公告日期2025-08-262025-04-282025-04-212024-10-29
审计意见(境内)标准无保留意见
TOP↑